scholarly article | Q13442814 |
P2093 | author name string | Subodh Verma | |
Jason R B Dyck | |||
Paul W M Fedak | |||
Donna L Beker | |||
Grant Masson | |||
Nikole J Byrne | |||
Nirmal Parajuli | |||
Jamie Boisvenue | |||
Jody L Levasseur | |||
P2860 | cites work | SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? | Q26750510 |
Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data | Q33763316 | ||
Longitudinal arrhythmogenic remodelling in a mouse model of longstanding pressure overload | Q34195594 | ||
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) | Q34264473 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction | Q35739201 | ||
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus | Q36622125 | ||
Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression. | Q36812665 | ||
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes | Q37586729 | ||
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart | Q37794503 | ||
Biology of human sodium glucose transporters | Q37870037 | ||
Fibrosis and heart failure | Q38057701 | ||
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot | Q38376619 | ||
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? | Q38845967 | ||
Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure. | Q38979963 | ||
Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolism | Q42703629 | ||
Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients | Q43203524 | ||
QRS duration and mortality in patients with congestive heart failure | Q44035548 | ||
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q47373645 | ||
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? | Q47384272 | ||
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose. | Q48283389 | ||
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. | Q51382208 | ||
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Q51707689 | ||
Empagliflozin's Fuel Hypothesis: Not so Soon. | Q52855314 | ||
Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias | Q54952185 | ||
Relation of dispersion of QRS and QT in patients with advanced congestive heart failure to cardiac and sudden death mortality | Q73763738 | ||
P433 | issue | 4 | |
P921 | main subject | empagliflozin | Q5373824 |
P304 | page(s) | 347-354 | |
P577 | publication date | 2017-08-04 | |
P1433 | published in | JACC. Basic to Translational Science | Q27727237 |
P1476 | title | Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. | |
P478 | volume | 2 |
Q89617548 | Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors |
Q58725666 | Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection |
Q89920670 | Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms |
Q59813541 | Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients |
Q98566233 | Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis |
Q64105820 | Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction |
Q93229030 | Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors |
Q93058591 | Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition |
Q98386175 | Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status |
Q58802559 | Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes |
Q90478430 | Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial |
Q90026288 | Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization |
Q96955195 | Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review |
Q64982195 | Refueling the Failing Heart: A Case for Sodium-Glucose Cotransporter 2 Inhibition in Cardiac Energy Homeostasis. |
Q90676214 | SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects |
Q92863133 | SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function |
Q61801176 | SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart |
Q61797815 | SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice |
Q63071416 | SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review |
Q91593292 | Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction |
Q89465086 | Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease |
Q64105830 | The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model |
Q92916727 | The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit |
Q92537722 | The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions |
Q60928393 | Update on heart failure management and future directions |